PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- (ANI or the Company) (Nasdaq: ANIP) today announced that following final ...

Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care ...

ANI Pharmaceuticals (ANIP) announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company ...

Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $62 from $60 and keeps a Hold rating on the shares as ...

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) had its price objective lifted by equities researchers at Truist Financial from $60.00 to $62.00 in a report released on Tuesday, Benzinga reports.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration ...

Ratings for ANI Pharmaceuticals ANIP were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

ANI Pharmaceuticals (NASDAQ:ANIP) announced that following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06% ...

Piper Sandler started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The firm issued an overweight ...

One company value investors might notice is ANI Pharmaceuticals (ANIP). ANIP is currently holding a Zacks Rank of #1 (Strong Buy) and a Value grade of A. We should also highlight that ANIP has a P ...

ANI Pharmaceuticals acquired Alimera Sciences, boosting its rare disease segment with a couple of durable ophthalmology ...